Walking on level, uphill, or downhill slopes for people with COPD
Official title: The Effect of Aerobic Exercise Training in Different Slope Types on Exercise Capacity, Respiratory Functions, Muscle Strength, and Functional Status in COPD Patients
Run by Acibadem University · NCT06283004 · Data updated 2026-11-12
This project will try treadmill walking on level, uphill, and downhill slopes twice a week for eight weeks to see if one type helps people with COPD walk farther and breathe better.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years and up |
| Sex | All |
| Enrollment | 51 (estimated) |
| Sponsor | Acibadem University Academic / other |
| Locations | 1 site (Istanbul, Eyüp Sultan) |
| Status | Recruiting |
| Started | April 9, 2025 |
| Main results expected | June 1, 2026 |
| Study ends | June 1, 2026 |
| Registry record updated | June 13, 2025 |
| Trial ID | NCT06283004 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ambulatory adults with COPD in GOLD groups A, B, or E who have no contraindications to exercise and score ≥24 on the mini‑mental test are ideal candidates.
✕Probably not a fit
Patients with very severe COPD (GOLD 4), hypoxemia, recent exacerbation, other significant respiratory disease, recent pulmonary surgery, active malignancy, or major uncontrolled cardiac/orthopedic/neurologic conditions are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, block‑assigned interventional study will enroll ambulatory adults with COPD and assign them to one of three eight‑week treadmill programs (level, uphill, or downhill walking) performed twice weekly. Baseline 6‑minute walk distance will set initial walking speed, and training speed and duration will be progressively increased during the program. Outcomes include exercise capacity, respiratory function, muscle strength, and functional status measured before and after the intervention. The protocol uses convenience sampling and targets a small sample size (24 total, 8 per group) calculated by a priori power analysis.
Why it matters
Potential benefit: If successful, this could identify a specific walking slope that improves exercise capacity, breathing, and leg muscle function to inform pulmonary rehabilitation programs.
How similar studies have gone: A few small prior studies have suggested downhill walking can help COPD patients, but the evidence base is limited and not yet conclusive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Being diagnosed with COPD (A, B, E groups according to GOLD assessment) * Ambulate on your own * Not having any contraindications for exercise * To be mentally appropriate (score 24 points and above in the mini mental test) Exclusion Criteria: * Being in GOLD 4 stage in spirometric evaluation * Presence of hypoxemia * Participation in another pulmonary rehabilitation program within the last 6 months * Having an exacerbation in the last 1 month * Being diagnosed with additional respiratory disease (asthma, bronchiectasis, etc.) * Having had pulmonary surgery * Having an orthopedic, neurological or cardiac disease that affects exercise * Having uncontrolled hypertension or diabetes * Presence of malignancy
Where it's running
-
Bezmialem Vakif University, Department of Physiotherapy and Rehabilitation
Istanbul, Eyüp Sultan, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Meryem Bektaş Karakuş, Res Asst.
- Email: meryem.bektas@acibadem.edu.tr
- Phone: +90 216 500 4195
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ensa?fentrine to help prevent COPD flare-ups in adults on standard care
This study tests whether ensifentrine (MK-5884) can help prevent moderate or severe COPD exacerbations compared with placebo in adults already receiving standard COPD treatment.
-
GSK Investigational Medicine GSK3862995B: two formulations in healthy adults
This early-phase study tests two formulations of GSK3862995B in healthy adults to see how the body handles the drug and whether it is safe and tolerable.
-
GSK5784283 added to standard COPD therapy vs placebo in moderate to very severe COPD
This study tests whether adding GSK5784283 to current COPD treatment reduces the rate of COPD flare-ups in adults with eosinophilic COPD and a history of exacerbations.
-
GSK5784283 added to standard COPD care versus placebo in adults with moderate to very severe COPD
This study tests whether adding GSK5784283 to a patient’s current COPD treatment helps reduce COPD flare-ups compared with a placebo in adults with eosinophilic COPD and a history of frequent exacerbations.
-
Brenipatide for adults with moderate-to-severe COPD
This study tests different doses of Brenipatide to see if it is safe and effective for adults with moderate-to-severe COPD, compared with placebo.
-
Early depemokimab treatment for COPD with type 2 (eosinophilic) inflammation
This trial will test whether adding depemokimab early to standard care helps adults with moderate-to-severe COPD who have type 2 (eosinophilic) inflammation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.